104 related articles for article (PubMed ID: 38861301)
1. IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma.
Badhrinarayanan S; Cotter C; Zhu H; Lin YC; Kudo M; Li D
Future Oncol; 2024 Jun; ():1-9. PubMed ID: 38861301
[TBL] [Abstract][Full Text] [Related]
2. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
[TBL] [Abstract][Full Text] [Related]
3. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Kim TW; Bedard PL; LoRusso P; Gordon MS; Bendell J; Oh DY; Ahn MJ; Garralda E; D'Angelo SP; Desai J; Hodi FS; Wainberg Z; Delord JP; Cassier PA; Cervantes A; Gil-Martin M; Wu B; Patil NS; Jin Y; Hoang T; Mendus D; Wen X; Meng R; Cho BC
JAMA Oncol; 2023 Nov; 9(11):1574-1582. PubMed ID: 37768658
[TBL] [Abstract][Full Text] [Related]
4. A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
Salani R; McCormack M; Kim YM; Ghamande S; Hall SL; Lorusso D; Barraclough L; Gilbert L; Guzman Ramirez A; Lu CH; Sabatier R; Colombo N; Hu Y; Krishnan V; Molinero L; Feng Y; Kim N; Castro M; Lin YG; Monk BJ
Int J Gynecol Cancer; 2024 Jun; ():. PubMed ID: 38858106
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Roussot N; Fumet JD; Limagne E; Thibaudin M; Hervieu A; Hennequin A; Zanetta S; Dalens L; Fourrier T; Galland L; Jacob P; Bertaut A; Rederstorff E; Chevalier C; Ghirardi S; Gilbert E; Khoukaz A; Martin E; Nicolet C; Quivrin M; Thibouw D; Vulquin N; Truc G; Rouffiac M; Ghiringhelli F; Mirjolet C
BMC Cancer; 2023 Nov; 23(1):1080. PubMed ID: 37946136
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Yamamoto N; Koyama T; Sato J; Yoshida T; Sudo K; Iwasa S; Kondo S; Yonemori K; Kawasaki A; Satake K; Shibata S; Shimizu T
Cancer Chemother Pharmacol; 2024 Jan; ():. PubMed ID: 38206370
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.
Shemesh CS; Wang Y; An A; Ding H; Chan P; Liu Q; Chen YW; Wu B; Wu Q; Wang X
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38451273
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
10. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Rudin CM; Liu SV; Soo RA; Lu S; Hong MH; Lee JS; Bryl M; Dumoulin DW; Rittmeyer A; Chiu CH; Ozyilkan O; Johnson M; Navarro A; Novello S; Ozawa Y; Tam SH; Patil NS; Wen X; Huang M; Hoang T; Meng R; Reck M
J Clin Oncol; 2024 Jan; 42(3):324-335. PubMed ID: 37976444
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
12. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
[TBL] [Abstract][Full Text] [Related]
13. Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.
Brazel D; Ou SI; Nagasaka M
Lung Cancer (Auckl); 2023; 14():1-9. PubMed ID: 36636263
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Garralda E; Oh DY; Italiano A; Bedard PL; Delord JP; Calvo E; LoRusso P; Wainberg Z; Cervantes A; Rodriguez-Vida A; Shemesh CS; Sane R; Mendus D; Ding H; Hendricks R; Meng R; Cho BC; Kim TW; Wu B
J Clin Pharmacol; 2024 May; 64(5):544-554. PubMed ID: 38105505
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S; Chen M; Cheng AL; Kaseb AO; Kudo M; Lee HC; Yopp AC; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Ma N; Spahn JH; Wang Y; Wu C; Chow PKH;
Lancet; 2023 Nov; 402(10415):1835-1847. PubMed ID: 37871608
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ;
Lancet; 2019 Jun; 393(10189):2404-2415. PubMed ID: 31079938
[TBL] [Abstract][Full Text] [Related]
19. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Nakagawa M; Inoue M; Ogasawara S; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kikuchi Y; Kogure T; Yumita S; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Taida T; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Shinozaki M; Kato J; Kato N
Cancer; 2023 Feb; 129(4):590-599. PubMed ID: 36426410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
